{"pmid":32294864,"title":"[Thinking on clinical rational use of TCM injection in the treatment of novel coronavirus pneumonia (COVID-19)].","text":["[Thinking on clinical rational use of TCM injection in the treatment of novel coronavirus pneumonia (COVID-19)].","Zhonghua Yi Xue Za Zhi","Wang, Z F","Wang, Y P","Zhang, H M","Fan, Y P","Lu, C","Wang, Y Y","32294864"],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Wang, Z F","Wang, Y P","Zhang, H M","Fan, Y P","Lu, C","Wang, Y Y"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32294864","week":"202016|Apr 13 - Apr 19","doi":"10.3760/cma.j.cn112137-20200221-00388","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266651123580930,"score":8.233237,"similar":[{"pmid":32122113,"title":"[Thinking on Clinical rational use of TCM injection in the treatment of novel coronavirus pneumonia (COVID-19)].","text":["[Thinking on Clinical rational use of TCM injection in the treatment of novel coronavirus pneumonia (COVID-19)].","Zhonghua Yi Xue Za Zhi","Wang, Z F","Wang, Y P","Zhang, H M","Fan, Y P","Lu, C","Wang, Y Y","32122113"],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Wang, Z F","Wang, Y P","Zhang, H M","Fan, Y P","Lu, C","Wang, Y Y"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32122113","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.issn.cn112137-20200221-00388","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134302695426,"score":190.4577},{"pmid":32289791,"title":"A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.","text":["A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.","Using Richardson and Davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for TRS (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. Rational use requires: (1) modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, (2) the use of clozapine levels for personalizing dosing, and (3) the use of slow and personalized titration. This may make clozapine as safe as possible and contribute to increased life expectancy and well-being. In the absence of data on COVID-19 in clozapine patients, clozapine possibly impairs immunological mechanisms and may increase pneumonia risk in infected patients. Psychiatrists should call their clozapine patients and families and explain to them that if the patient develops fever or flu-like symptoms, the psychiatrist should be called and should consider halving the clozapine dose. If the patient is hospitalized with pneumonia, the treating physician needs to assess for symptoms of clozapine intoxication since halving the dose may not be enough for all patients; consider decreasing it to one-third or even stopping it. Once the signs of inflammation and fever have disappeared, the clozapine dose can be slowly increased to the prior dosage level.","Psychother Psychosom","de Leon, Jose","Ruan, Can-Jun","Schoretsanitis, Georgios","De Las Cuevas, Carlos","32289791"],"abstract":["Using Richardson and Davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for TRS (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. Rational use requires: (1) modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, (2) the use of clozapine levels for personalizing dosing, and (3) the use of slow and personalized titration. This may make clozapine as safe as possible and contribute to increased life expectancy and well-being. In the absence of data on COVID-19 in clozapine patients, clozapine possibly impairs immunological mechanisms and may increase pneumonia risk in infected patients. Psychiatrists should call their clozapine patients and families and explain to them that if the patient develops fever or flu-like symptoms, the psychiatrist should be called and should consider halving the clozapine dose. If the patient is hospitalized with pneumonia, the treating physician needs to assess for symptoms of clozapine intoxication since halving the dose may not be enough for all patients; consider decreasing it to one-third or even stopping it. Once the signs of inflammation and fever have disappeared, the clozapine dose can be slowly increased to the prior dosage level."],"journal":"Psychother Psychosom","authors":["de Leon, Jose","Ruan, Can-Jun","Schoretsanitis, Georgios","De Las Cuevas, Carlos"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289791","week":"202016|Apr 13 - Apr 19","doi":"10.1159/000507638","keywords":["Asian continental ancestry group/genetics","COVID-19","Clozapine, blood","Clozapine/adverse effects","Clozapine/metabolism","Clozapine/toxicity","Drug labeling","Infection","Inflammation","Mortality/drug effects"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Asians"],"_version_":1664071627245092864,"score":60.509014},{"pmid":32186172,"title":"[Thoughts and practice on the treatment of severe and critical new coronavirus pneumonia].","text":["[Thoughts and practice on the treatment of severe and critical new coronavirus pneumonia].","Severe and critical coronavirus pneumonia 2019 (COVID-19) often occurs in elder patients with multiple comorbidities, and severe hypoxemia events are an important factor in the deterioration of some cases. The critical type of COVID-19 could progress to acute respiratory distress syndrome and multi-organ dysfunction, which are the most important causes of death. Early start with non-invasive ventilation (NIV) against the possible physiological abnormalities could be helpful to improve prognosis. Close monitoring of oxygenation, reducing patients' oxygen consumption, active psychological intervention, and rapidly dealing with severe hypoxemia events are the key factors for the successful treatment of NIV. In addition, active adjuvant therapy is also important, such as correcting coagulation dysfunction, providing proper nutritional support, accurate volume control, and safe individualized blood glucose monitoring and control.","Zhonghua Jie He He Hu Xi Za Zhi","Li, H C","Ma, J","Zhang, H","Cheng, Y","Wang, X","Hu, Z W","Li, N","Deng, X R","Zhang, Y","Zheng, X Z","Yang, F","Weng, H Y","Dong, J P","Liu, J W","Wang, Y Y","Liu, X M","32186172"],"abstract":["Severe and critical coronavirus pneumonia 2019 (COVID-19) often occurs in elder patients with multiple comorbidities, and severe hypoxemia events are an important factor in the deterioration of some cases. The critical type of COVID-19 could progress to acute respiratory distress syndrome and multi-organ dysfunction, which are the most important causes of death. Early start with non-invasive ventilation (NIV) against the possible physiological abnormalities could be helpful to improve prognosis. Close monitoring of oxygenation, reducing patients' oxygen consumption, active psychological intervention, and rapidly dealing with severe hypoxemia events are the key factors for the successful treatment of NIV. In addition, active adjuvant therapy is also important, such as correcting coagulation dysfunction, providing proper nutritional support, accurate volume control, and safe individualized blood glucose monitoring and control."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, H C","Ma, J","Zhang, H","Cheng, Y","Wang, X","Hu, Z W","Li, N","Deng, X R","Zhang, Y","Zheng, X Z","Yang, F","Weng, H Y","Dong, J P","Liu, J W","Wang, Y Y","Liu, X M"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186172","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn112147-20200312-00320","keywords":["COVID-19","Early intervention","Non-invasive ventilation","Very severe hypoxemia events","acute respiratory distress syndrome"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Blood Glucose"],"_version_":1663352133805670401,"score":56.525333},{"pmid":32203710,"pmcid":"PMC7118603","title":"Rational use of face masks in the COVID-19 pandemic.","text":["Rational use of face masks in the COVID-19 pandemic.","Lancet Respir Med","Feng, Shuo","Shen, Chen","Xia, Nan","Song, Wei","Fan, Mengzhen","Cowling, Benjamin J","32203710"],"journal":"Lancet Respir Med","authors":["Feng, Shuo","Shen, Chen","Xia, Nan","Song, Wei","Fan, Mengzhen","Cowling, Benjamin J"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203710","week":"202013|Mar 23 - Mar 29","doi":"10.1016/S2213-2600(20)30134-X","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663352133642092544,"score":53.29045},{"pmid":32125126,"title":"[Management and clinical thinking of Coronavirus Disease 2019].","text":["[Management and clinical thinking of Coronavirus Disease 2019].","In December 2019, the 2019 novel coronavirus pneumonia (NCP, officially named Coronavirus Disease 2019(COVID-19) by the World Health Organization) broke out in Wuhan, Hubei, and it quickly spread to the whole country and abroad. The situation was at stake. The sudden and serious COVID-19 epidemic has brought us a lot of urgent problems. How to effectively control the spread of COVID-19? When does the population infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to effectively treat with existing drugs? Can it successfully improve the survival rate of critically patients? In response to the above questions, we put forward corresponding suggestions and reflections from the perspective of the infectious clinician.","Zhonghua Gan Zang Bing Za Zhi","Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q","32125126"],"abstract":["In December 2019, the 2019 novel coronavirus pneumonia (NCP, officially named Coronavirus Disease 2019(COVID-19) by the World Health Organization) broke out in Wuhan, Hubei, and it quickly spread to the whole country and abroad. The situation was at stake. The sudden and serious COVID-19 epidemic has brought us a lot of urgent problems. How to effectively control the spread of COVID-19? When does the population infection rate rise to its peak? What will eventually be the number of infected patients? How to make early diagnosis? What effective antiviral drugs are available? How to effectively treat with existing drugs? Can it successfully improve the survival rate of critically patients? In response to the above questions, we put forward corresponding suggestions and reflections from the perspective of the infectious clinician."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Ma, K","Chen, T","Han, M F","Guo, W","Ning, Q"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125126","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.issn.1007-3418.2020.0002","keywords":["2019 novel coronavirus","Corona virus disease 2019","Diagnosis","Treatment"],"source":"PubMed","locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352134292209664,"score":51.56761}]}